deaths from infectious diseases, especially tuberculosis. Any intervention that facilitated hospital discharge was considered of primary importance, and for many years, the count of patients discharged from inpatient care was the standard outcome measure of the effectiveness of a new treatment. Not only did more discharges mean a reduction in hospital beds and money saved by cutting staff, but also, as a consequence of deinstitutionalization, patients could be reintegrated into their families and communities, where recovery, as everyone agreed, would occur more readily. Institutions had acquired a bad name. 6 The move away from institutions happened, however, before economics and travel patterns changed family structures; before not just fathers, but mothers as well, worked outside the home; and before grandparents either remained employed postretirement or were housed in retirement communities or old-age homes. When there was no family member at home to supervise convalescent patients, the movement to reintegrate patients with families was transformed into a movement to refer patients to boarding homes or hostels, where optimal care was lacking. Hospital numbers fell, but patients returned to hospital often. The readmission rate became the standard outcome measure. When patients were evicted from their place of residence and did not return to hospital, they ended up homeless on the street or, poor and undernourished, they committed petty crimes and were jailed. The number of those with mental illness among the homeless and the prison population increased. A recent study in San Francisco reports that nearly three-quarters of a sample of severely mentally ill individuals had been arrested at some time. 7 The percentage of mental illness among the homeless and among prisoners could have become an outcome measure in itself, but although studied, it never attained the status it deserves. Instead, reduction in symptom scores is today counted as the best and most frequently used gauge of outcome, although return to work, 8 the quality and extent of one's social network, and satisfaction with treatment are sometimes taken into account as well, usually globally in the form of the GAF score. 9 Recently, the much-cited CATIE study used treatment continuation as a new measure of effectiveness. 10 In this paper, I examine a different outcome-health and mortality among the mentally ill, a measure suggested last year by Drew. 11 
Health
The general health of individuals with a diagnosis of schizophrenia in 2006 is far from good. Rates of obesity, smoking, angina, and respiratory symptoms are significantly higher than in the general population. 12 In the CATIE study, the 10-year risk of cardiovascular disease was significantly elevated in subjects treated for schizophrenia, compared with age-matched control subjects. Schizophrenia patients, compared with control subjects, had significantly higher rates of smoking (68% and 35%, respectively), diabetes (13% and 3%, respectively), and hypertension (27% and 17%, respectively), as well as lower HDL cholesterol levels (43.7 and 49.3 mg/dL, respectively) (P < 0.001). 13 In hospital, medical and surgical procedures for individuals with schizophrenia are accompanied by twice as many adverse events as occur in those without schizophrenia. For patients with schizophrenia, being in respiratory failure or suffering from sepsis results in twice the number of intensive care unit admissions and twice as many deaths as for those free of schizophrenia, according to a new study. 14 The median relative increase in length of stay attributable to this diagnosis is at least 10 days, with comparatively elevated hospital costs of about US$20 000. 14
Mortality
Among schizophrenia patients, mortality rates are higher than in the general population for diseases of the circulatory, digestive, endocrine, nervous, and respiratory systems, as well as for suicide and for undetermined death. Smoking-related fatal disease was found to be especially prominent in a 13-year longitudinal follow-up study conducted in England. 15 More than two-thirds of patients with schizophrenia (compared with about one-half in the general population) die of coronary heart disease. The chief risk factors for this excess risk of cardiovascular death are cigarette smoking and obesity, with resultant dyslipidemia, insulin resistance and diabetes, and hypertension. 16 The story differs when it comes to malignancy rates. Only one study 17 has reported higher rates in a schizophrenia population when compared with the general population. Most other studies find equal rates for most cancers. 18, 19 From 16% to more than 25% of individuals diagnosed with schizophrenia are reported to be victims of violence at some time in their lives. 7, 20 A research group in the United Kingdom has reported that men with schizophrenia have an increased risk of dying by homicide, especially when they are involved in alcohol and drug use. 21 Suicide rates among schizophrenia sufferers are especially high-10 to 20 times the rate in the general population. A recent study in Wales has shown that current rates of suicide among those with schizophrenia and other psychoses appear to be twentyfold higher than they were in the period 1875 to 1924. 22 Where the average life expectancy of the general population of the United States is 76 years (72 years for men and 80 years for women), the corresponding figure for the population with schizophrenia is 61 years (57 years for men and 65 years for women). In other words, compared with the general population, patients with schizophrenia have a 20% reduced life expectancy. Contributing to this is the socioeconomic condition of those with schizophrenia (which may lessen their access to health care); difficulties, inherent in the condition, of following medical regimens; and the possibility that psychiatric treatment increases the risks. 23, 24 The move from hospital to the community seems to have resulted in a relative rise in cardiovascular deaths and unnatural deaths for both men and women, but most pronounced in men, 25 probably via the route of homelessness and consequent lack of supervision and health care.
This important question of whether deinstitutionalization increases mortality has been specifically addressed in a population of individuals with mental retardation-where no evidence for such an association was found-but individuals with mental retardation are probably a somewhat different population from individuals with schizophrenia, the latter being perhaps less amenable to close supervision of their health needs. 26 When the same question was addressed in a population of long-term psychiatrically ill patients discharged into the community in Scotland between 1977 and 1994, the authors found that, of 6776 individuals discharged, 1994 (29%) had died by the end of the follow-up study, representing 732 more deaths than expected. Deaths from suicide, homicide, accident, and undetermined cause were increased but accounted for only 197 of the excess deaths. Deaths from respiratory disease were 4 times higher than expected, and deaths from other causes, including cardiovascular disease, were also high. 27 Because increasing percentages of the homeless suffer from psychotic illness, it is relevant to examine mortality rates among this population. Mortality in the homeless population in Philadelphia has been found to be 4 times that of the general population. 28 In the Philadelphia study, injuries, heart disease, liver disease, poisoning, and ill-defined conditions account for 73% of all the deaths among the homeless. 28 Among homeless people suffering from schizophrenia in Sydney, Australia, the death rate was found to be 3 to 4 times that of the general population and most pronounced among younger individuals. 29 In Finland, patients in their early years of illness experienced increased mortality that manifested shortly after a steep reduction in the number of hospital beds in that country, but this was not true for older patients with schizophrenia. 30, 31 A study in France found that excess in mortality among patients with schizophrenia was, among all variables studied, most directly correlated with the dosages of antipsychotic medication received. 32 In the United States, high rates of death, and especially of fatal injury, have also been reported in people treated with antipsychotics. 33 Further, a study from Finland found that the number of antipsychotic drugs used correlated with mortality, the relative risk increasing by 2.50 per prescribed drug. 34 Shortly after phenothiazines were introduced for the treatment of schizophrenia, they were already shown to elevate serum triglyceride and total cholesterol levels. The prevalence of hyperlipidemia in subjects either taking or not taking antipsychotic medication (n = 5654) was carefully studied in a prospective, population-based birth cohort (the Northern Finland 1966 Birth Cohort). 35 The subjects, then aged 31 years, were clinically examined in 1997-1998. Lipid levels in those who used both atypical and typical medication, and also in those who used only typical medication, were high. The elevated risk of hyperlipidemia in those using antipsychotic medication was independent of the other risk factors assessed (specifically, sex, diet, waist circumference, physical exercise, smoking, and alcohol consumption).
In a cross-sectional British study, severe mental illness was associated with raised 10-year coronary heart disease risk scores, lower HDL-cholesterol levels, raised cholesterol-HDL cholesterol ratios, DM, and smoking. These associations, which varied significantly with age, could not be explained by medication use or by socioeconomic status. 36 In a cross-sectional Swedish study of patients treated for schizophrenia, the prevalence of the metabolic syndrome was 34.6% (32.8% for men and 38% for women) and highest for participants aged 40 to 49 years, with clozapine-treated subjects having the highest prevalence (48%). Men also had high rates of hypertension (49.2%), and women showed low HDL cholesterol (40.2%) and abdominal obesity (75.0%). Obesity (BMI > 30) was present in 36.8% of all study subjects. 37 Relatively recently, the US Food and Drug Administration issued a bulletin stating that atypical antipsychotic medications increased mortality among elderly patients. A new retrospective cohort study in Pennsylvania involved 22 890 patients aged 65 years or older who used either conventional or atypical antipsychotic medication between 1994 and 2003. Mortality rates were analyzed together with their proximity to the initiation of antipsychotic therapy, and the investigators found that conventional antipsychotic medications were associated with a significantly higher adjusted risk of death, compared with atypical antipsychotic medications. The greatest increases in risk occurred soon after therapy was initiated and at relatively higher dosages of the conventional antipsychotic medications. 38, 39 These results may or may not be equally applicable to a younger population.
A study conducted between September 1996 and June 2001 determined rates of DM in patients with schizophrenia treated for at least 3 months with atypical (n = 1826) or conventional (n = 617) antipsychotics. Patients treated with atypical antipsychotics were found to have a moderately increased risk of DM, relative to those treated with conventional antipsychotics, as measured by Cox proportional hazards models. 40 Using data from the National Hospital Discharge Survey, a recent study conducted a trend analysis for the prevalence of DM in patients with schizophrenia and those without known mental illness. According to the results, DM risks were the same in the 2 groups during the era before atypical antipsychotics (1979 to 1989) and shortly after their introduction (1990 to 1995); however, during the period 1996 to 2001, the net difference in DM prevalence grew at an increasing rate (0.7% per year, P < 0.001). By 2001, over a base DM prevalence of 10% in patients with schizophrenia, 3.1 percentage points (P = 0.016) could be attributed to the use of atypical antipsychotic drugs. This growth was most pronounced among female African-American patients and patients in the group aged 35 to 49 years. 41 A recent comprehensive literature review weighed the evidence for and against an association between glucose or lipid dysregulation and 8 separate second-generation antipsychotics currently available in the United States and (or) Europe, specifically, clozapine, olanzapine, risperidone, quetiapine, zotepine, amisulpride, ziprasidone, and aripiprazole. Treatment with clozapine or olanzapine was associated with the greatest risk of clinically significant weight gain. Risperidone, quetiapine, amisulpride, and zotepine generally showed low-to-moderate levels of mean weight gain. Treatment with ziprasidone or aripiprazole was associated with the least weight gain. The different secondgeneration antipsychotics were associated with differing effects on glucose and lipid metabolism, with clozapine and olanzapine most often increasing the risk of DM and dyslipidemia. The risk for risperidone appears smaller and is still undetermined for quetiapine, zotepine, amisulpride, ziprasidone, and aripiprazole. In general, a drug's weight-gain liability tends to predict roughly three-quarters of the risk of insulin resistance, dyslipidemia, and hyperglycemia. 42 Diabetes in patients using antipsychotics drugs may go unnoticed. In treated patients not diagnosed with diabetes, 30.1% were by chance found to have abnormally elevated fasting plasma glucose. Occult hyperglycemia was found significantly more often in patients receiving clozapine (P = 0.001), compared with other drugs. 43 Antipsychotics are a significant risk factor for sudden cardiac death. A study of 481 744 individuals in Tennessee showed a correlation between moderate dosages of antipsychotics and the risk of sudden cardiac death, especially marked in those with prior cardiovascular disease. 44 Prolongation of the QTc interval, a known side effect of some antipsychotic drugs, can cause fatal arrhythmia and sudden death. Current evidence suggests that 5% to 10% of those suffering cardiac arrhythmias carry a silent mutation in a gene responsible for the congenital long QTc syndrome and that the use of a QTc-prolonging drug can increase that risk almost threefold (more so in women than in men and more so at higher dosages). 45
Conclusion
The conclusion to be drawn from this selective review is that the combination of schizophrenic illness, lifestyle, inconsistent medical care, and antipsychotic treatment in 2006 is not good for one's health. One problem is the fact that most patients with a diagnosis of schizophrenia live more or less on their own, battling a serious illness with insufficient support. 46 Perhaps what is needed from a health policy point of view is both education and financial compensation for family caregivers. Services directed toward supporting the families of individuals with serious and persistent mental illnesses remain scarce but could theoretically improve health outcomes immeasurably. 47, 48 Perhaps a wide network of foster families who look after vulnerable individuals, once so common in Europe, could work in modern North America; it does appear to work in the province of Québec. 49 Safer drugs, of course, need to be developed.
We also need to examine the moral value we place on autonomy, the basis of modern bioethics, 50 as applied to the population with severe mental illness. Is it for the patient's benefit that autonomy has become our highest value, trumping what used to motivate physicians-that is, doing good? Is choosing to neglect their health a free choice made by individuals with schizophrenia, or is it a direct result of professional negligence 51,52 that ultimately leads to unnecessary deaths? We used to say that schizophrenia patients were dying with their rights on, refusing treatment and dying for the lack of it. Since the new era of antipsychotics, patients are still dying, although they are now more often treated. Psychotic symptoms are well controlled while hyperglycemia rates and hyperlipidemia rates skyrocket, and our profession helplessly looks on.
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Résumé : Une mesure du résultat de la schizophrénie : la mortalité
Objectif : Déterminer le résultat actuel de la schizophrénie, au moyen du taux de mortalité comme mesure du résultat.
Méthode : Les statistiques récentes sur la santé, le suicide, les victimes de violence et la mortalité ont été examinées.
Résultats : La santé générale des personnes souffrant de schizophrénie est assaillie par la négligence, de mauvais choix de style de vie, et les traitements actuels qui augmentent le taux de mortalité.
Conclusion : La mortalité est en hausse dans la schizophrénie, et il incombe aux médecins et aux planificateurs des soins de santé d'intervenir.
